Literature DB >> 8599875

Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus.

S M Allen1, J P Duffy, S J Darnton, M H Cullen, H R Matthews.   

Abstract

We evaluated the effect of brief neoadjuvant chemotherapy in patients with apparently operable adenocarcinoma of the oesophagus. Two courses of mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2;MIC) were given followed by evaluation of response by barium swallow and computed tomography scan. Of 20 patients, 17 completed both courses and 4 (20%) showed a partial response. Toxicity was generally mild and consisted principally of nausea and vomiting. Altogether, 15 patients were surgically explored; resection was completed in 12 patients, 3 of whom died in hospital (25%). Neoadjuvant therapy with MIC offers no advantage over surgery alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599875     DOI: 10.1007/s002800050418

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Left-sided subtotal oesophagectomy for carcinoma.

Authors:  H R Matthews; A Steel
Journal:  Br J Surg       Date:  1987-12       Impact factor: 6.939

2.  Preoperative chemotherapy in esophageal carcinoma.

Authors:  D P Kelsen
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 3.  Ifosfamide in experimental tumor systems.

Authors:  A Goldin
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

4.  Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy.

Authors:  R Fein; D P Kelsen; N Geller; M Bains; P McCormack; M F Brennan
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

5.  Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus.

Authors:  A A Forastiere; M Gennis; M B Orringer; F P Agha
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

6.  Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.

Authors:  D A Karlin; J R Stroehlein; R W Bennetts; R D Jones; L J Heifetz; P S Mahal
Journal:  Cancer Treat Rep       Date:  1982-08

7.  A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus.

Authors:  S J Walker; S M Allen; A Steel; M H Cullen; H R Matthews
Journal:  Clin Oncol (R Coll Radiol)       Date:  1991-11       Impact factor: 4.126

8.  Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.

Authors:  M H Cullen; R Joshi; A D Chetiyawardana; C M Woodroffe
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

9.  A phase II study of carboplatin in adenocarcinoma of the oesophagus.

Authors:  A Steel; M H Cullen; P W Robertson; H R Matthews
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites.

Authors:  J Powell; C C McConkey
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  1 in total

Review 1.  MicroRNA and its roles in esophageal cancer.

Authors:  Yu Fang; Dianchun Fang; Jianguo Hu
Journal:  Med Sci Monit       Date:  2012-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.